Abstract
The promising high-throughput metagenomics sequencing including both taxonomic 16S ribosomal RNA and shotgun sequencing has greatly facilitated the study of gut microbiota and its association with disease. Intestinal microbiota influences host immunity and may profoundly interact with mucosal environment and induce its perturbation by various mechanisms involving genetic and metabolic by-products. Current evidence suggests a primary and fundamental role of microbiota dysbiosis in driving the progress of the adenoma-carcinoma sequence and metastasis of colorectal cancer (CRC). Interestingly, microbiome dysbiosis-based signatures are promising biomarkers to predict prognosis, therapy response to cancer immunotherapy, drug adverse events, as well as survival outcomes. The focus of this chapter is to critically review the role of gut microbiota in colorectal carcinogenesis and its potential in biomarker development and progress of the rapidly evolving oncoimmunology. We also discuss the perspectives of using microbiota in the clinical decision-making workflow.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abed J, Emgård JE, Zamir G et al (2016) Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed gal-GalNAc. Cell Host Microbe 20(2):215–225. https://doi.org/10.1016/j.chom.2016.07.006
Ahmed J, Kumar A, Parikh K et al (2018) Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Onco Targets Ther 7(11):e1507670. https://doi.org/10.1080/2162402X.2018.1507670
Ahn J, Sinha R, Pei Z et al (2013) Human gut microbiome and risk for colorectal cancer. J Natl Cancer Instit 105(24):1907–1911. https://doi.org/10.1093/jnci/djt300
Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM (2017) Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 14(6):356–365. https://doi.org/10.1038/nrgastro.2017.20
Allen J, Sears CL (2019) Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Med 11(1):11. https://doi.org/10.1186/s13073-019-0621-2
Almeida A, Mitchell AL, Boland M et al (2019) A new genomic blueprint of the human gut microbiota. Nature 568(7753):499–504. https://doi.org/10.1038/s41586-019-0965-1
Amitay EL, Krilaviciute A, Brenner H (2018) Systematic review: gut microbiota in fecal samples and detection of colorectal neoplasms. Gut Microbes 9(4):293–307. https://doi.org/10.1080/19490976.2018.1445957
Bashir A, Miskeen AY, Bhat A, Fazili KM, Ganai BA (2015) Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. Eur J Cancer Prev 24(5):373–385. https://doi.org/10.1097/CEJ.0000000000000116
Belcheva A, Irrazabal T, Robertson SJ et al (2014) Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158(2):288–299. https://doi.org/10.1016/j.cell.2014.04.051
Brennan CA, Garrett WS (2016) Gut microbiota, inflammation, and colorectal cancer. Annu Rev Microbiol 70:395–411. https://doi.org/10.1146/annurev-micro-102215-095513
Brennan CA, Garrett WS (2019) Fusobacterium nucleatum – symbiont, opportunist and oncobacterium. Nat Rev Microbiol 17(3):156–166. https://doi.org/10.1038/s41579-018-0129-6
Brim H, Yooseph S, Zoetendal EG et al (2013) Microbiome analysis of stool samples from African Americans with colon polyps. PLoS One 8(12):e81352. https://doi.org/10.1371/journal.pone.0081352
Bullman S, Pedamallu CS, Sicinska E et al (2017) Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science 358(6369):1443–1448. https://doi.org/10.1126/science.aal5240
Burns MB, Montassier E, Abrahante J et al (2018) Colorectal cancer mutational profiles correlate with defined microbial communities in the tumor microenvironment. PLoS Genet 14(6):e1007376. https://doi.org/10.1371/journal.pgen.1007376
Castellarin M, Warren RL, Freeman JD et al (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22(2):299–306. https://doi.org/10.1101/gr.126516.111
Chaput N, Lepage P, Coutzac C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368–1379. https://doi.org/10.1093/annonc/mdx108
Chen HM, Yu YN, Wang JL et al (2013) Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr 97(5):1044–1052. https://doi.org/10.3945/ajcn.112.046607
Chen J, Domingue JC, Sears CL (2017) Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin Immunol 32:25–34. https://doi.org/10.1016/j.smim.2017.08.001
Chen D, Wu J, Jin D, Wang B, Cao H (2018) Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer 145:2021–2031. https://doi.org/10.1002/ijc.32003
Clavel T, Lagkouvardos I, Hiergeist A (2016) Microbiome sequencing: challenges and opportunities for molecular medicine. Expert Rev Mol Diagn 16(7):795–805. https://doi.org/10.1080/14737159.2016.1184574
Davidson RM, Epperson LE (2018) Microbiome sequencing methods for studying human diseases. Methods Mol Biol 1706:77–90. https://doi.org/10.1007/978-1-4939-7471-9_5
Dejea CM, Fathi P, Craig JM et al (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359(6375):592–597. https://doi.org/10.1126/science.aah3648
Derosa L, Routy B, Kroemer G, Zitvogel L (2018a) The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Onco Targets Ther 7(6):e1434468. https://doi.org/10.1080/2162402X.2018.1434468
Derosa L, Hellmann MD, Spaziano M et al (2018b) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29(6):1437–1444. https://doi.org/10.1093/annonc/mdy103
Ding X, Li Q, Li P et al (2019) Long-term safety and efficacy of fecal microbiota transplant in active ulcerative colitis. Drug Saf 42:869. https://doi.org/10.1007/s40264-019-00809-2
Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ (2012) The Warburg effect dictates the mechanism of butyrate mediated histone acetylation and cell proliferation. Mol Cell 48(4):612–626. https://doi.org/10.1016/j.molcel.2012.08.033
Drewes JL, White JR, Dejea CM et al (2017) High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microbiomes 3:34. https://doi.org/10.1038/s41522-017-0040-3
Dubin K, Callahan MK, Ren B et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391. https://doi.org/10.1038/ncomms10391
Elkrief A, El Raichani L, Richard C et al (2019) Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Onco Targets Ther 8(4):e1568812. https://doi.org/10.1080/2162402X.2019.1568812
Encarnação JC, Abrantes AM, Pires AS et al (2015) Revisit dietary fiber on colorectal cancer: butyrate and its role on prevention and treatment. Cancer Metastasis Rev 34(3):465–478. https://doi.org/10.1007/s10555-015-9578-9
Feng Q, Liang S, Jia H et al (2015) Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 6:6528. https://doi.org/10.1038/ncomms7528
Flanagan L, Schmid J, Ebert M et al (2014) Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 33(8):1381–1390. https://doi.org/10.1007/s10096-014-2081-3
Flemer B, Lynch DB, Brown JMR et al (2017a) Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66(4):633–643. https://doi.org/10.1136/gutjnl-2015-309595
Flemer B, Warren RD, Barrett MP et al (2017b) The oral microbiota in colorectal cancer is distinctive and predictive. Gut, pii: gutjnl-2017-314814. https://doi.org/10.1136/gutjnl-2017-314814
Frankel AE, Coughlin LA, Kim J et al (2017) Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19(10):848–855. https://doi.org/10.1016/j.neo.2017.08.004
Ganesh K, Stadler ZK, Cercek A et al (2019) Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 16:361. https://doi.org/10.1038/s41575-019-0126-x
Gao Z, Guo B, Gao R, Zhu Q, Qin H (2015) Microbiota disbiosis is associated with colorectal cancer. Front Microbiol 6:20. https://doi.org/10.3389/fmicb.2015.00020
Geng J, Fan H, Tang X, Zhai H, Zhang Z (2013) Diversified pattern of the human colorectal cancer microbiome. Gut Pathog 5:2. https://doi.org/10.1186/1757-4749-5-2
Gholizadeh P, Eslami H, Kafil HS (2017) Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomed Pharmacother 89:918–925. https://doi.org/10.1016/j.biopha.2017.02.102
Gide TN, Wilmott JS, Scolyer RA, Long GV (2017) Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res 24(6):1260–1270. https://doi.org/10.1158/1078-0432.CCR-17-2267
Gnanaprakasam JN, Estrada-Muniz E, Vega L (2015) The anacardic 6-pentadecyl salicylic acid induces macrophage activation via the phosphorylation of ERK1/2, JNK, P38 kinases and NF-kappaB. Int Immunopharmacol 29:808–817
Goedert JJ, Gong Y, Hua X et al (2015) Fecal microbiota characteristics of patients with colorectal adenoma detected by screening: a population-based study. EBioMedicine 2(6):597–603. https://doi.org/10.1016/j.ebiom.2015.04.010
Gonçalves P, Martel F (2013) Butyrate and colorectal cancer: the role of butyrate transport. Curr Drug Metab 14(9):994–1008
Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R (2019) The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med 8(1):9. https://doi.org/10.1186/s40169-019-0225-x
Goodrich JK, Di Rienzi SC, Poole AC et al (2014) Conducting a microbiome study. Cell 158(2):250–262. https://doi.org/10.1016/j.cell.2014.06.037
Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103. https://doi.org/10.1126/science.aan4236
Guevarra LA Jr, Afable ACF, Belza PJO et al (2018) Immunogenicity of a Fap2 peptide mimotope of fusobacterium nucleatum and its potential use in the diagnosis of colorectal cancer. Infect Agent Cancer 13:11. https://doi.org/10.1186/s13027-018-0184-7
Gur C, Ibrahim Y, Isaacson B et al (2015) Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42(2):344–355. https://doi.org/10.1016/j.immuni.2015.01.010
Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026
Han YW (2015) Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol 23:141–147. https://doi.org/10.1016/j.mib.2014.11.013
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150. https://doi.org/10.1038/s41568-019-0116-x
Herzberg B, Campo MJ, Gainor JF (2016) Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist 22(1):81–88. https://doi.org/10.1634/theoncologist.2016-0189
Hibberd AA, Lyra A, Ouwehand AC et al (2017) Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol 4(1):e000145. https://doi.org/10.1136/bmjgast-2017-000145
Hollands A, Corriden R, Gysler G, Dahesh S, Olson J, Raza Ali S, Kunkel MT, Lin AE, Forli S, Newton AC (2016) Natural product anacardic acid from cashew nut shells stimulates neutrophil extracellular trap production and bactericidal activity. J Biol Chem 291:13964–13973
Huang Q, Peng Y, Xie F (2018) Fecal fusobacterium nucleatum for detecting colorectal cancer: a systematic review and meta-analysis. Int J Biol Markers 1724600818781301. https://doi.org/10.1177/1724600818781301
Ji B, Nielsen J (2015) From next-generation sequencing to systematic modeling of the gut microbiome. Front Genet 6:219. https://doi.org/10.3389/fgene.2015.00219
Jiang JW, Chen XH, Ren Z et al (2019) Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 18(1):19–27. https://doi.org/10.1016/j.hbpd.2018.11.002
Keenan TE, Burke KP, Van Allen EM (2019) Genomic correlates of response to immune checkpoint blockade. Nat Med 25(3):389–402. https://doi.org/10.1038/s41591-019-0382-x
Keku TO, Dulal S, Deveaux A, Jovov B, Han X (2015) The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 308(5):G351–G363. https://doi.org/10.1152/ajpgi.00360.2012
Kong JC, Guerra GR, Pham T et al (2019) Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 62(4):498–508. https://doi.org/10.1097/DCR.0000000000001332
Kostic AD, Gevers D, Pedamallu CS et al (2012) Genomic analysis identifies association of fusobacterium with colorectal carcinoma. Genome Res 22(2):292–298. https://doi.org/10.1101/gr.126573.111
Kroemer G, Zitvogel L (2018) Cancer immunotherapy in 2017: the breakthrough of the microbiota. Nat Rev Immunol 18(2):87–88. https://doi.org/10.1038/nri.2018.4
Li W, Deng Y, Chu Q et al (2019) Gut microbiome and cancer immunotherapy. Cancer Lett 447:41–47. https://doi.org/10.1016/j.canlet.2019.01.015
Louis P, Hold GL, Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12(10):661–672. https://doi.org/10.1038/nrmicro3344
Mani S (2017) Microbiota and breast cancer. Prog Mol Biol Transl Sci 151:217–229. https://doi.org/10.1016/bs.pmbts.2017.07.004
Mao Q, Jiang F, Yin R et al (2018) Interplay between the lung microbiome and lung cancer. Cancer Lett 415:40–48. https://doi.org/10.1016/j.canlet.2017.11.036
McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO (2013) Fusobacterium is associated with colorectal adenomas. PLoS One 8(1):e53653. https://doi.org/10.1371/journal.pone.0053653
Mehta RS, Nishihara R, Cao Y et al (2017) Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol 3(7):921–927. https://doi.org/10.1001/jamaoncol.2016.6374
Mei Z, Liu Y, Liu C et al (2014) Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 110(6):1595–1605. https://doi.org/10.1038/bjc.2014.46
Mima K, Sukawa Y, Nishihara R et al (2015) Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 1(5):653–661. https://doi.org/10.1001/jamaoncol.2015.1377
Mima K, Nishihara R, Qian ZR et al (2016) Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65(12):1973–1980. https://doi.org/10.1136/gutjnl-2015-310101
Mira-Pascual L, Cabrera-Rubio R, Ocon S et al (2015) Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol 50(2):167–179. https://doi.org/10.1007/s00535-014-0963-x
Morgan XC, Huttenhower C (2012) Chapter 12: Human microbiome analysis. PLoS Comput Biol 8(12):e1002808. https://doi.org/10.1371/journal.pcbi.1002808
Murphy CL, OʼToole PW, Shanahan F (2019) The gut microbiota in causation, detection, and treatment of cancer. Am J Gastroenterol 114:1036–1042. https://doi.org/10.14309/ajg.0000000000000075
Najafi M, Farhood B, Mortezaee K (2019) Contribution of regulatory T cells to cancer: a review. J Cell Physiol 234(6):7983–7993. https://doi.org/10.1002/jcp.27553
Nakatsu G, Li X, Zhou H et al (2015) Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 6:8727. https://doi.org/10.1038/ncomms9727
Narayanan V, Peppelenbosch MP, Konstantinov SR (2014) Human fecal microbiome-based biomarkers for colorectal cancer. Cancer Prev Res (Phila) 7(11):1108–1111. https://doi.org/10.1158/1940-6207.CAPR-14-0273
Narula N, Kassam Z, Yuan Y et al (2017) Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 23(10):1702–1709. https://doi.org/10.1097/MIB.0000000000001228
Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A et al (2019) Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: independent of oncogenetic features. J Cell Physiol 234(4):4768–4777. https://doi.org/10.1002/jcp.27273
Paramsothy S, Kamm MA, Kaakoush NO et al (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389(10075):1218–1228. https://doi.org/10.1016/S0140-6736(17)30182-4
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
Peng BJ, Cao CY, Li W et al (2018) Diagnostic performance of intestinal fusobacterium nucleatum in colorectal cancer: a meta-analysis. Chin Med J 131(11):1349–1356. https://doi.org/10.4103/0366-6999.232814
Peters BA, Dominianni C, Shapiro JA et al (2016) The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome. 4:69. https://doi.org/10.1186/s40168-016-0218-6
Pitt JM, Vétizou M, Waldschmitt N et al (2016) Fine-tuning cancer immunotherapy: optimizing the gut microbiome. Cancer Res 76(16):4602–4607. https://doi.org/10.1158/0008-5472.CAN-16-0448
Purcell RV, Visnovska M, Biggs PJ, Schmeier S, Frizelle FA (2017) Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep 7:11590. https://doi.org/10.1038/s41598-017-11237-6
Pyo JS, Kang G (2017) Immunotherapy in advanced melanoma: a network meta-analysis. Immunotherapy 9(6):471–479. https://doi.org/10.2217/imt-2016-0143
Ramos A, Hemann MT (2017) Drugs, bugs, and cancer: fusobacterium nucleatum promotes chemoresistance in colorectal cancer. Cell 170(3):411–413. https://doi.org/10.1016/j.cell.2017.07.018
Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G (2018a) The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol 15(6):382–396. https://doi.org/10.1038/s41571-018-0006-2
Routy B, Le Chatelier E, Derosa L et al (2018b) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97. https://doi.org/10.1126/science.aan3706
Rozek LS, Schmit SL, Greenson JK et al (2016) Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst 108(8):djw027. https://doi.org/10.1093/jnci/djw027
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14(2):195–206. https://doi.org/10.1016/j.chom.2013.07.012
Russo E, Bacci G, Chiellini C et al (2018) Preliminary comparison of oral and intestinal human microbiota in patients with colorectal cancer: a pilot study. Front Microbiol 8:2699. https://doi.org/10.3389/fmicb.2017.02699
Sarangi AN, Goel A, Aggarwal R (2019) Methods for studying gut microbiota: a primer for physicians. J Clin Exp Hepatol 9(1):62–73. https://doi.org/10.1016/j.jceh.2018.04.016
Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13(11):800–812. https://doi.org/10.1038/nrc3610
Sekirov I, Russell SL, Antunes LC et al (2010) Gut microbiota in health and disease. Physiol Rev 90(3):859–904. https://doi.org/10.1152/physrev.00045.2009
Shah MS, DeSantis TZ, Weinmaier T et al (2017) Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer. Gut 67(5):882–891. https://doi.org/10.1136/gutjnl-2016-313189
Sharma P, Allison JP (2015) Future of immune checkpoint therapy. Science 348(6230):56–61. https://doi.org/10.1126/science.aaa8172
Singh N, Gurav A, Sivaprakasam S et al (2014) Activation of the receptor (Gpr109a) for niacin and the commensal metabolite butyrate suppresses colonic inflammation and carcinogenesis. Immunity 40(1):128–139. https://doi.org/10.1016/j.immuni.2013.12.007
Sinha R, Ahn J, Sampson JN et al (2016) Fecal microbiota, fecal metabolome, and colorectal cancer interrelations. PLoS One 11(3):e0152126. https://doi.org/10.1371/journal.pone.0152126
Sivan A, Corrales L, Hubert N et al (2015) Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–1089. https://doi.org/10.1126/science.aac4255
Staley C, Hamilton MJ, Vaughn BP et al (2017) Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota. Pragmatic cohort study. Am J Gastroenterol 112(6):940–947. https://doi.org/10.1038/ajg.2017.6
Syn NL, Teng MWL, Mok TSK, Soo RA (2017) De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 18(12):e731–e741. https://doi.org/10.1016/S1470-2045(17)30607-1
Sze MA, Schloss PD (2018) Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors [published correction appears in MBio. 2018 Oct 16;9(5)]. MBio 9(3):e00630–e00618. https://doi.org/10.1128/mBio.00630-18
Tahara T, Yamamoto E, Suzuki H et al (2014) Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 74(5):1311–1318. https://doi.org/10.1158/0008-5472.CAN-13-1865
Takeuchi Y, Nishikawa H (2016) Roles of regulatory T cells in cancer immunity. Int Immunol 28(8):401–409. https://doi.org/10.1093/intimm/dxw025
Tan PS, Aguiar P Jr, Haaland B et al (2018) Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – a systematic review and network meta-analysis of 3024 participants. Lung Cancer 115:84–88. https://doi.org/10.1016/j.lungcan.2017.11.017
Thomas AM, Jesus EC, Lopes A et al (2016) Tissue-associated bacterial alterations in rectal carcinoma patients revealed by 16S rRNA community profiling. Front Cell Infect Microbiol 6:179. https://doi.org/10.3389/fcimb.2016.00179
Thomas AM, Manghi P, Asnicar F et al (2019) Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med 25(4):667–678. https://doi.org/10.1038/s41591-019-0405-7
Tjalsma H, Boleij A, Marchesi JR et al (2012) A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 10(8):575–582. https://doi.org/10.1038/nrmicro2819
Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461. https://doi.org/10.1016/j.ccell.2015.03.001
Wang J, Jia H (2016) Metagenome-wide association studies: fine-mining the microbiome. Nat Rev Microbiol 14(8):508–522. https://doi.org/10.1038/nrmicro.2016.83
Wang Y, Wiesnoski DH, Helmink BA et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis [published correction appears in Nat Med. 2018 Nov 27]. Nat Med 24(12):1804–1808. https://doi.org/10.1038/s41591-018-0238-9
Warren RL, Freeman DJ, Pleasance S et al (2013) Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 1:16. https://doi.org/10.1186/2049-2618-1-16
Wei Z, Cao S, Liu S et al (2016) Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget 7(29):46158–46172. https://doi.org/10.18632/oncotarget.10064
Wei SC, Levine JH, Cogdill AP et al (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170(6):1120–1133.e17. https://doi.org/10.1016/j.cell.2017.07.024
Wirbel J, Pyl PT, Kartal E et al (2019) Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 25(4):679–689. https://doi.org/10.1038/s41591-019-0406-6
Wong SH, Zhao L, Zhang X et al (2017) Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153(6):1621–1633.e6. https://doi.org/10.1053/j.gastro.2017.08.022
Wu N, Yang X, Zhang R et al (2013) Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol 66(2):462–470. https://doi.org/10.1007/s00248-013-0245-9
Wu X, Zhang T, Chen X et al (2019) Microbiota transplantation: targeting cancer treatment. Cancer Lett 452:144–151. https://doi.org/10.1016/j.canlet.2019.03.010
Yang Y, Jobin C (2018) Colorectal cancer: hand-in-hand – colorectal cancer metastasizes with microorganisms. Nat Rev Gastroenterol Hepatol 15(3):133–134. https://doi.org/10.1038/nrgastro.2017.186
Yang GY, Shamsuddin AM (1996) Gal-GalNAc: a biomarker of colon carcinogenesis. Histol Histopathol 11(3):801–806
Yang J, Tan Q, Fu Q et al (2017a) Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications. Breast Cancer 24(2):220–228. https://doi.org/10.1007/s12282-016-0734-z
Yang Y, Weng W, Peng J et al (2017b) Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating TLR4 signaling to NFκB, upregulating expression of microRNA-21. Gastroenterology 152(4):851–866.e24. https://doi.org/10.1053/j.gastro.2016.11.018
Yu J, Feng Q, Wong SH et al (2017a) Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 66(1):70–78. https://doi.org/10.1136/gutjnl-2015-309800
Yu T, Guo F, Yu Y et al (2017b) Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170(3):548–563.e16. https://doi.org/10.1016/j.cell.2017.07.008
Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I (2016) Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 5(7):1481–1491. https://doi.org/10.1002/cam4.732
Zackular JP, Baxter NT, Iverson KD et al (2013) The gut microbiome modulates colon tumorigenesis. mBio 4(6):e00692–e00613. https://doi.org/10.1128/mBio.00692-13
Zackular JP, Rogers MAM, Ruffin MT, Schloss PD (2014) The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila) 7(11):1112–1121. https://doi.org/10.1158/1940-6207.CAPR-14-0129
Zackular JP, Baxter NT, Chen GY, Schloss PD (2016) Manipulation of the gut microbiota reveals role in colon tumorigenesis. mSphere 1(1):e00001–e00015. https://doi.org/10.1128/mSphere.00001-15
Zeller G, Tap J, Voigt AY et al (2014) Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 10(11):766. https://doi.org/10.15252/msb.20145645
Zhang X, Zhu X, Cao Y, Fang JY, Hong J, Chen H (2019) Fecal fusobacterium nucleatum for the diagnosis of colorectal tumor: a systematic review and meta-analysis. Cancer Med 8(2):480–491. https://doi.org/10.1002/cam4.1850
Zhao S, Gao G, Li W et al (2019) Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer 130:10–17. https://doi.org/10.1016/j.lungcan.2019.01.017
Zitvogel L, Galluzzi L, Viaud S et al (2015) Cancer and the gut microbiota: an unexpected link. Sci Transl Med 7(271):271ps1. https://doi.org/10.1126/scitranslmed.3010473
Zou S, Fang L, Lee MH (2017) Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep (Oxf) 6(1):1–12. https://doi.org/10.1093/gastro/gox031
Authors’ Contributions
KE wrote the chapter. MA and AM supervised the writing process.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
El Bairi, K., Amrani, M., Maleb, A. (2020). Gut Microbiota, Next-Generation Sequencing, Immune-Checkpoint Inhibitors, and Colorectal Cancer: How Hot Is the Link?. In: El Bairi, K. (eds) Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. Springer, Cham. https://doi.org/10.1007/978-3-030-53821-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-53821-7_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53820-0
Online ISBN: 978-3-030-53821-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)